Looking Ahead: Future Perspectives and Unmet Need in HER+ Breast Cancer

Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Preliminary results from a phase 1 trial show an objective response rate of 13.3% with avutometinib, abemaciclib, and fulvestrant in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer.